AdvanCell Closes A$18M Series B Funding Led by Morningside
14.9.2022 17:16:00 EEST | Business Wire | Press release
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Will Present New Evidence on Long-term Outcomes in Allergen Immunotherapy at EAACI 202611.6.2026 11:09:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Academy of Allergy and Clinical Immunology (EAACI) congress, taking place from June 12 to 15 in Istanbul, Turkey. The company will host a scientific symposium entitled “From Nobel Prize discovery to AIT clinical evidence: Shaping pathways to respiratory allergy remission.”Three leading international experts will explore how landmark breakthroughs in immunology have deepened our understanding of immune tolerance, presenting emerging data on remission and long-term outcomes in respiratory allergy. Together, these insights reinforce AIT’s disease-modifying potential and its growing role in personalised medicine. “EAACI 2026 is an exceptional forum for the global allergy community to exchange knowledge and advance the field. Stallergenes Greer is proud contribute to these conversations, bringing together world-leading experts in pur
NIPPON KINZOKU’s “FINE PIPE” Series Welded Drawn Pipes Outperforming Seamless Pipes11.6.2026 11:01:00 EEST | Press release
NIPPON KINZOKU CO., LTD. (TOKYO:5491) (Headquarters: Minato-ku, Tokyo) has commercialized its “FINE PIPE” series *1, -welded drawn pipes that outperform traditional seamless pipes. By leveraging its unique expertise as a material manufacturer and proprietary processing technologies (welding, drawing, and annealing), the company delivers high-quality, eco-friendly, and cost-effective solutions. FINE PIPE is already widely adopted across various sectors, including automotive parts, measuring instruments, and industrial equipment, to meet the most demanding precision requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611874307/en/ In response to the growing demand for higher performance and faster processing in analytical and medical devices, NIPPON KINZOKU has developed two innovative products based on its FINE PIPE technology: "High-Precision Inner Surface" small-diameter tubes and "FINE PEEK-ST" stainless steel
Comrade Trustee Services goes live with Smartstream’s Air, the AI reconciliation and data automation solution11.6.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Comrade Trustee Services Limited (CTSL), trustee for the Defence Force Retirement Benefit Fund in Papua New Guinea, has gone live with Smartstream’s Air, the AI reconciliation and data automation solution – cutting processing times from eight hours to under five minutes. The go-live delivers a fully automated, straight-through reconciliation workflow, enabling CTSL to significantly improve operational efficiency, accuracy and auditability. CTSL operates in a complex data environment, reconciling multiple file types, including fixed-length files and PDFs, requiring advanced matching logic. To manage this and scale, CTSL adopted Air for its ability to handle diverse data structures, custom integrations, and ETL-based transformations, delivering high automation and match rates. This has replaced manual data collection and Excel pre-processing, cutting processing
Wolters Kluwer enhances its Libra legal AI workspace in Italy by adding content specializations for One and integrating with Kleos11.6.2026 10:00:00 EEST | Press release
Wolters Kluwer Legal & Regulatory announced today new content and feature integrations in its legal AI workspace Libra by Wolters Kluwer for the Italian market. Customers will have access to additional expert-generated content in compliance, criminal law and tax law, and profit from the integration with Kleos, the cloud-based practice management solution for law firms. Designed to support the daily work of legal professionals, Libra by Wolters Kluwer combines advanced AI functionalities with trusted sources and authoritative, author-generated legal content. Within a single environment, it enables research, analysis and drafting activities based on reliable sources, while maintaining full control over results and quality. By integrating additional expert content from One, Wolters Kluwer’s leading legal research platform, Libra offers even more focused and up-to-date content, enabling more precise analysis of specific topics, and foster direct integration between legal research and opera
Pleo Announces New Agentic Capabilities, Changing the Face of Financial Management and Decision-Making11.6.2026 10:00:00 EEST | Press release
Pleo, Europe's first and most trusted strategic finance platform, today announces a suite of AI agents that handle routine spend management autonomously, so finance leaders can focus on decisions rather than administrative tasks. Finance teams are under growing pressure: 45% of European companies say their current processes slow them down, and leaders describe approval workflows as so cumbersome they struggle to operate at the required speed. Meanwhile, 73% believe the future of finance teams and professionals depends on the comprehensive understanding and use of AI, yet 63% say AI skills, training and confidence are severely lagging. Pleo's agentic AI addresses this gap. Starting with beta testing in July, Pleo is moving toward a model where specialised agents execute routine work autonomously, surfacing only the exceptions that genuinely need human judgment. Jeppe Rindom, CEO and Founder of Pleo comments: “Agentic AI gives finance leaders a clear path out of the admin and back to the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom